AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although ZAK sustained CML cell proliferation by promoting AKT activity, loss of ZAK function paradoxically reduced the cytotoxic effects of BCR::ABL1 inhibitors.